SS Innovations International (SSII) Registration filing summary

Company overview and business model

• Designs, manufactures, and markets the SSi Mantra, an advanced, affordable surgical robotic system for multiple specialties, aiming to democratize access to robotic surgery, especially in underserved markets.

• Commercially launched in late 2022, with 168 systems installed as of December 31, 2025, primarily in India and select international markets.

• Generates revenue through outright sales, deferred/installment payments, and pay-per-procedure models, with recurring revenue from instruments, accessories, and services.

• Holds regulatory approvals in India and several other countries; seeking FDA and EU approvals, with submissions made and decisions expected in 2026.

• Focuses on cost-effective, scalable technology, including telesurgery and tele-mentoring capabilities, to address barriers in global adoption.

Financial performance and metrics

• Revenue for the year ended December 31, 2025, is expected to be approximately $43.0 million, up 108% from $20.6 million in 2024.

• Net loss for the year ended December 31, 2024, was $19.15 million, compared to $20.88 million in 2023.

• Gross profit for the nine months ended September 30, 2025, was $13.2 million, up from $4.5 million in the same period of 2024.

• Cash and cash equivalents as of September 30, 2025, were $5.7 million; total assets were $69.6 million.

• Company has relied on debt and equity financing, including significant related-party convertible notes, to fund operations.

Use of proceeds and capital allocation

• Net proceeds of approximately $45.8 million (or $52.8 million if the underwriters' option is exercised in full) are intended for working capital, manufacturing expansion, bulk component ordering, global clinical trials, additional office and manufacturing space, and regional marketing offices.

• Proceeds will also support regulatory efforts and general corporate purposes.